At a Glance
- Companies: Eli Lilly; Repertoire Therapeutics
- Location: Indianapolis, USA (Lilly); Cambridge, Massachusetts, USA (Repertoire)
- Deal value: $150m upfront; up to $1.85bn in milestones; tiered royalties
- Focus area: T‑cell‑focused autoimmune therapies (including a clinical‑stage program and discovery assets)
- Next steps: Joint development and commercialisation of partnered programs
What happened?
Eli Lilly and Repertoire Therapeutics have entered a broad strategic collaboration to jointly develop T‑cell‑focused autoimmune therapies. The deal includes an undisclosed clinical‑stage program and multiple discovery‑stage assets from Repertoire’s pipeline. Lilly is paying $150 million upfront and up to $1.85 billion in development, regulatory and commercial milestones, plus tiered royalties on future sales.
Why does it matter?
Autoimmune diseases remain a major unmet‑need area with many patients sub‑optimally controlled on existing therapies. By targeting T‑cell biology, the partnership aims to deliver more precise, durable treatments that modulate immune responses rather than broadly suppress immunity. For Lilly, the deal deepens its immunology portfolio and diversifies its autoimmune pipeline beyond current marketed products.
Who’s behind it?
Repertoire Therapeutics is a biotech applying systems immunology and multi‑omics to decode T‑cell biology and develop targeted autoimmune therapies. Eli Lilly brings global development, regulatory and commercial infrastructure, along with an established immunology and autoimmune franchise. The alliance reflects Lilly’s continued push into next‑generation immune‑modulating modalities.
How was it achieved?
The collaboration leverages Repertoire’s proprietary platforms for identifying and validating T‑cell‑targeted mechanisms, combined with Lilly’s drug‑development and clinical‑trial expertise. The upfront payment and milestone structure allow Repertoire to advance its pipeline while sharing risk and reward with Lilly, who gains access to a portfolio of programs spanning different stages of development.
What’s next?
The companies will jointly progress the clinical‑stage asset through later‑phase trials and expand work on the discovery‑stage programs. Lilly is expected to take the lead on later‑stage development and global commercialisation, while Repertoire continues to contribute its T‑cell biology and translational insights. The partnership may also serve as a template for future immune‑focused collaborations.
What are people saying?
Lilly leadership has framed the deal as a way to “expand our immunology footprint with novel T‑cell‑targeted approaches,” while Repertoire has described the alliance as validation of its systems‑immunology platform and a major step toward bringing precision autoimmune therapies to patients.